SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like Targeted therapy pralsetinib improves outcomes in RET fusion-positive NSCLCs April 1, 2026 Chan Zuckerberg Initiative funds Notre Dame research on aging and neurodegeneration February 21, 2024 Gut bacteria and urinary infections linked, offering new angles for treatment April 30, 2024
Chan Zuckerberg Initiative funds Notre Dame research on aging and neurodegeneration February 21, 2024